News Headlines
-
Vetter Earns Prestigious Honors Across All Core Categories In The 13th Annual CDMO Leadership Awards
3/26/2024
Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma, small pharma and overall respondents.
-
Biocytogen Enters Collaboration With ABL Bio To Develop New Bispecific Antibody-Drug Conjugates
3/25/2024
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
-
AbbVie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases
3/25/2024
AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
-
Novo Nordisk To Acquire Cardior Pharmaceuticals And Strengthen Pipeline In Cardiovascular Disease
3/25/2024
Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.
-
Andelyn Biosciences And Grace Science, LLC Partner To Tech Transfer Phase I/II/III Manufacturing Of A Suspension Process Adeno-Associated Virus (AAV) Gene Therapy For NGLY1 Deficiency
3/25/2024
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Grace Science, LLC, to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy for Phase I/II/III clinical trial material for the treatment of NGLY1 Deficiency.
-
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession And Board Changes
3/22/2024
Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that its Board of Directors unanimously approved the conclusion of its review of strategic alternatives that was initiated in March 2023, and, concurrently therewith, announced several strategic updates related to its operations on a stand-alone basis.
-
Upperton Joined By Professor Dame Sarah Gilbert, To Officially Open New Development And GMP Manufacturing Facility.
3/22/2024
UK-based contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions was joined by Oxford/AstraZeneca COVID-19 vaccine co-inventor Professor Dame Sarah Gilbert, biotech industry representatives and local leaders to celebrate the official opening of a new 50,000 square foot development and GMP manufacturing facility in Nottingham.
-
Pharmazz Inc. And Dr. Reddy's Laboratories Have Entered Into A Licensing Agreement To Market Centhaquine (Lyfaquin) As A Resuscitative Agent For Hypovolemic Shock In India
3/22/2024
Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat critically ill patients, announced that it has entered into a license agreement with Dr. Reddy's Laboratories Limited ("Dr. Reddy's"), a global pharmaceutical company, to commercialize a first-in-class innovative drug Centhaquine in India.
-
Charles River Announces Extension Of Gene Therapy Manufacturing Alliance With NUS Yong Loo Lin School Of Medicine
3/21/2024
Charles River Laboratories International, Inc. and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement.
-
Batavia And Candel Collaborate To Develop Therapeutics Against Glioma Brain Tumors
3/21/2024
Today, Batavia Biosciences, a leading Contract Development and Manufacturing Organization, announces a new partnership with Candel Therapeutics, Inc. a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer.